EU Body Recommends Use Of Remdesivir To Treat COVID-19

Henrietta Brewer
June 29, 2020

The recommended dose for adults and pediatric patients is 200 mg on the first day with a follow-up of 100 mg for the next five days.

The chairman of the Hetero Group also stated that "with the rising number of COVID-19 cases in the nation, the endorsement for the supply of Covifor (Remdesivir) drug can prove to be a game-changer because clinical results are positive and satisfactory". Gujarat and Tamil Nadu are the other two states that will receive the first batch of the drug.

The company is sure about enough stock to provide to the present requirements of the drug.

AFP reports that at least two major United States studies have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients. In the second phase, the company would send the vials to Bhubaneswar, besides Kolkata, Indore, Bhopal, Lucknow, Patna, Ranchi, Vijayawada, Kochi, Thiruvananthapuram and Goa.


He further said that we are working closely with the government and the medical community so that public and private medical institutions across the country can quickly access the "COVIFOR" drug.

The European Medicines Agency (EMA) stated that the anti-inflammatory drug ought to be authorized to be used to treat individuals with all the coronavirus.

On June 1, the inventor of the medication, a biotech company called Gilead, stated that its experimental drug increased symptoms of COVID-19 when it contributed to hospitalized, moderately-ill patients.

The move sees remdesivir become the first medicine against COVID-19 to be recommended for authorisation in the EU.


The EMA endorsement means physicians can prescribe the Gilead drug in Europe once the European Commission, the EU executive, gives its approval, which is now a formality expected over the coming week.

In May, domestic pharma firms Hetero, Cipla and Jubilant Life Sciences entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of remdesivir.

The decision to back the drug's approval in this setting is mainly based on data from the US National Institute of Allergy and Infectious Diseases (NIAID) study NIAID-ACTT-11, which found that patients treated with remdesivir recovered after about 11 days, compared with 15 days for patients given placebo.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER